Open Save New
FeedNavigator / National Library of Health Sciences
AddTurpeenniemi-Hujanen, T.

»My Articles

»Latest Feeds

»Popular Feeds
Search Feed Catalog by Name:
Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell/follicular grade 3B lymphoma.Turpeenniemi-Hujanen, T.571 dayssaveRefWorks
Prognostic significance of Twist, ZEB1 and Slug in peripheral T-cell lymphomas.Turpeenniemi-Hujanen, T.573 dayssaveRefWorks
Thioredoxin-1 as a biological predictive marker for selecting diffuse large B-cell lymphoma patients for etoposide-containing treatment.Turpeenniemi-Hujanen, T.651 dayssaveRefWorks
Significance of bulky mass and residual tumor-Treated with or without consolidative radiotherapy-To the risk of relapse in DLBCL patients.Turpeenniemi-Hujanen, T.725 dayssaveRefWorks
Twist and Zeb1 expression identify Mycosis fungoides patients with low risk of disease progression.Turpeenniemi-Hujanen, T.830 dayssaveRefWorks
Sunitinib First-line Treatment in Metastatic Renal Cell Carcinoma: Costs and Effects.Turpeenniemi-Hujanen, T.838 dayssaveRefWorks
Peroxiredoxin 6 Serum Levels and Risk of Neutropenic Infections in Diffuse Large B-cell Lymphoma.Turpeenniemi-Hujanen, T.855 dayssaveRefWorks
Incidence of solid cancer in patients with follicular lymphoma.Turpeenniemi-Hujanen, T.899 dayssaveRefWorks
Risk of secondary haematological malignancies in patients with follicular lymphoma: an analysis of 1028 patients treated in the rituximab era.Turpeenniemi-Hujanen, T.928 dayssaveRefWorks
Nuclear factor erythroid 2-related factors 1 and 2 are able to define the worst prognosis group among high-risk diffuse large B cell lymphomas treated with R-CHOEP.Turpeenniemi-Hujanen, T.1068 dayssaveRefWorks
Treatment of Diffuse Large B-cell Lymphoma in Elderly Patients; Replacing Doxorubicin with either Epirubicin or Etoposide (VP-16).Turpeenniemi-Hujanen, T.1116 dayssaveRefWorks
Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP.Turpeenniemi-Hujanen, T.1199 dayssaveRefWorks
Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial.Turpeenniemi-Hujanen, T.1326 dayssaveRefWorks
Case Report: Chemotherapy in Conjunction With Blood-Brain Barrier Disruption for a Patient With Germ Cell Tumor With Multiple Brain Metastases.Turpeenniemi-Hujanen, T.1327 dayssaveRefWorks
R-Bendamustine in the treatment of nodular lymphocyte-predominant Hodgkin lymphoma.Turpeenniemi-Hujanen, T.1397 dayssaveRefWorks
Strong Prolyl Hydroxylase Domain 1 Expression Predicts Poor Outcome in Radiotherapy-treated Patients with Classical Hodgkin's Lymphoma.Turpeenniemi-Hujanen, T.1481 dayssaveRefWorks
Integrin alpha 10, CD44, PTEN, cadherin-11 and lactoferrin expressions are potential biomarkers for selecting patients in need of central nervous system prophylaxis in diffuse large B-cell lymphoma.Turpeenniemi-Hujanen, T.1591 dayssaveRefWorks
Low Rap1-interacting factor 1 and sirtuin 6 expression predict poor outcome in radiotherapy-treated Hodgkin lymphoma patients.Turpeenniemi-Hujanen, T.1622 dayssaveRefWorks
Real-time monitoring of human blood-brain barrier disruption.Turpeenniemi-Hujanen, T.1763 dayssaveRefWorks
Promising treatment results with blood brain barrier disruption (BBBD) based immunochemotherapy combined with autologous stem cell transplantation (ASCT) in patients with primary central nervous system lymphoma (PCNSL).Turpeenniemi-Hujanen, T.1916 dayssaveRefWorks
Strong KDM4B and KDM4D Expression Associates with Radioresistance and Aggressive Phenotype in Classical Hodgkin Lymphoma.Turpeenniemi-Hujanen, T.1948 dayssaveRefWorks
Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry.Turpeenniemi-Hujanen, T.2057 dayssaveRefWorks
Total peroxiredoxin expression is associated with survival in patients with follicular lymphoma.Turpeenniemi-Hujanen, T.2131 dayssaveRefWorks
Similar chemokine receptor profiles in lymphomas with central nervous system involvement - possible biomarkers for patient selection for central nervous system prophylaxis, a retrospective study.Turpeenniemi-Hujanen, T.2381 dayssaveRefWorks
High intensity of cytoplasmic peroxiredoxin VI expression is associated with adverse outcome in diffuse large B-cell lymphoma independently of International Prognostic Index.Turpeenniemi-Hujanen, T.2449 dayssaveRefWorks
Constant pattern of relapse in primary central nervous lymphoma patients treated with high-dose methotrexate combinations. A Finnish retrospective study.Turpeenniemi-Hujanen, T.2503 dayssaveRefWorks
Antithrombin III is probably not a suitable biomarker for diagnosis of primary central nervous system lymphoma.Turpeenniemi-Hujanen, T.2519 dayssaveRefWorks
Oxidative stress markers and mitochondrial antioxidant enzyme expression are increased in aggressive Hodgkin lymphomas.Turpeenniemi-Hujanen, T.2844 dayssaveRefWorks
Combination of strong MMP-2 and weak TIMP-2 immunostainings is a significant prognostic factor in endometrial carcinoma.Turpeenniemi-Hujanen, T.2952 dayssaveRefWorks
[Chemotherapy in conjunction with blood brain barrier disruption in the treatment of primary central nervous system lymphoma].Turpeenniemi-Hujanen, T.3001 dayssaveRefWorks
Increased expression of CIP2A in aggressive subtypes of B-cell lymphoma.Turpeenniemi-Hujanen, T.3125 dayssaveRefWorks
Cell cycle regulation score predicts relapse-free survival in non-germinal center diffuse large B-cell lymphoma patients treated by means of immunochemotherapy.Turpeenniemi-Hujanen, T.3205 dayssaveRefWorks
Circulating matrix metalloproteinases MMP-9 and MMP-2/TIMP-2 complex are associated with spontaneous early pregnancy failure.Turpeenniemi-Hujanen, T.3287 dayssaveRefWorks
2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.Turpeenniemi-Hujanen, T.3295 dayssaveRefWorks
Oxidative stress and redox state-regulating enzymes have prognostic relevance in diffuse large B-cell lymphoma.Turpeenniemi-Hujanen, T.3329 dayssaveRefWorks
Biological roles and prognostic values of the epithelial-mesenchymal transition-mediating transcription factors Twist, ZEB1 and Slug in diffuse large B-cell lymphoma.Turpeenniemi-Hujanen, T.3335 dayssaveRefWorks
Snail promotes an invasive phenotype in lung carcinoma.Turpeenniemi-Hujanen, T.3345 dayssaveRefWorks
Tumor tissue inhibitor of metalloproteinases-1 (TIMP-1) in hormone-independent breast cancer might originate in stromal cells, and improves stratification of prognosis together with nodal status.Turpeenniemi-Hujanen, T.3576 dayssaveRefWorks
Immunoreactivity for TIMP-2 is associated with a favorable prognosis in endometrial carcinoma.Turpeenniemi-Hujanen, T.3645 dayssaveRefWorks
Long-term prognosis of breast cancer detected by mammography screening or other methods.Turpeenniemi-Hujanen, T.3671 dayssaveRefWorks
Expression and Prognostic Evaluation of Oxidative Stress Markers in an Immunohistochemical Study of B-cell Derived Lymphomas.Turpeenniemi-Hujanen, T.3771 dayssaveRefWorks
Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study.Turpeenniemi-Hujanen, T.3777 dayssaveRefWorks
Specific TP53 mutations predict aggressive phenotype in head and neck squamous cell carcinoma : a retrospective archival study.Turpeenniemi-Hujanen, T.3918 dayssaveRefWorks
8-hydroxydeguanosine and nitrotyrosine are prognostic factors in urinary bladder carcinoma.Turpeenniemi-Hujanen, T.3931 dayssaveRefWorks
A prognostic index in skin melanoma through the combination of matrix metalloproteinase-2, Ki67, and p53.Turpeenniemi-Hujanen, T.3982 dayssaveRefWorks
Very high quantitative tumor HER2 content and outcome in early breast cancer.Turpeenniemi-Hujanen, T.4001 dayssaveRefWorks
Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer.Turpeenniemi-Hujanen, T.4009 dayssaveRefWorks
p53 in head and neck cancer: Functional consequences and environmental implications of TP53 mutations.Turpeenniemi-Hujanen, T.4049 dayssaveRefWorks
Front-line bevacizumab in serous epithelial ovarian cancer: biomarker analysis of the FINAVAST trial.Turpeenniemi-Hujanen, T.4294 dayssaveRefWorks
Increased matrix metalloproteinases 2 and 9 and tissue inhibitor of matrix metalloproteinase 2 expression is associated with progression from vulvar intraepithelial neoplasia to invasive carcinoma.Turpeenniemi-Hujanen, T.4370 dayssaveRefWorks
 XML / RSS feed
next »